Table 4. Detailed treatment flow for individual patients.
| Patient # | Diagnosis | Sex | Age, yr | Stage | Pre-HDCT treatment | Tumor status | 1st HDCT regimen | 2nd HDCT regimen | Event, mon* | Outcome, mon* | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prior to 1st HDCT | After 1st HDCT | 3 months after 2nd HDCT | |||||||||||
| HR | 1 | Epithelioid sarcoma | F | 13.6 | 4 | CTx + Surgery + RTx | SD | PD | — | MEC | — | Progression (2) | DOD (25) |
| 2 | Osteosarcoma | F | 14.7 | 4B | CTx + RTx | PD | PD | — | MEC | — | Progression (3) | DOD (9) | |
| 3 | Ewing | M | 0.6 | 1 | CTx | CR | CR | CR | CTE | CM | — | NED (66) | |
| 4 | Osteosarcoma | M | 14.3 | 4 | CTx + Surgery + RTx | CR | — | — | MEC | — | TRM (2) | DOC (2) | |
| 5 | Ewing | M | 17.1 | 4 | CTx + Surgery | CR | CR | — | MEC | — | Relapse (5) | DOD (13) | |
| 6 | Ewing | M | 14.6 | 4 | CTx + Surgery | PR | SD | — | MEC | — | — | NED (57) | |
| 7 | DSRCT | M | 17.0 | 4 | CTx | PR | PD | SD | CTE | CM | Progression (5) | DOD (9) | |
| 8 | Ewing | M | 16.0 | 4 | CTx + Surgery | CR | CR | CR | CTE | CM | Relapse (17) | DOD (47) | |
| 9 | Ewing | M | 16.2 | 4 | CTx + Surgery | CR | CR | CR | CTE | CM | Relapse (17) | DOD (24) | |
| 10 | Ewing | F | 8.3 | 4 | CTx + Surgery | PD | — | — | CTE | — | TRM (0) | DOC (0) | |
| 11 | DSRCT | M | 14.4 | 4 | CTx + Surgery | CR | CR | — | CTE | — | Relapse (7) | DOD (16) | |
| 12 | Synovial sarcoma | F | 16.9 | 4 | CTx + Surgery + RTx | PD | PD | PD | CTE | CM | Progression (2) | Follow up loss (18) | |
| 13 | RMS | M | 16.8 | 4 | CTx + RTx | CR | CR | CR | CTE | CM | Relapse (8) | Follow up loss (25) | |
| 14 | Osteosarcoma | F | 10.9 | 1A | CTx + Surgery | CR | CR | CR | CTE | CM | — | NED (18) | |
| 15 | Ewing | M | 18.7 | 4 | CTx + RTx | SD | SD | PD | CTE | CM | Progression (2) | DOD (9) | |
| 16 | DSRCT | M | 9.7 | 3 | CTx + RTx | CR | CR | — | CTE | — | — | NED (14) | |
| 17 | Inflammatory myofibroblastic tumor | M | 16.3 | 4 | CTx + Surgery | CR | PD | — | CTE | — | Relapse (3) | DOD (8) | |
| 18 | Synovial sarcoma | F | 11.8 | 4 | CTx + RTx | PR | SD | SD | CTE | TBI-CM | Progression (6) | AWD (6) | |
| Relapse | 19 | Ewing | F | 5.7 | 4 | CTx + RTx | PD | PD | — | CEC | — | Progression (1) | DOD (3) |
| 20 | Ewing | M | 13.5 | 4 | CTx | PD | SD | — | CTE | — | Progression (5) | DOD (5) | |
| 21 | MPNST | M | 13.7 | 1 | CTx + Surgery + RTx | PR | PD† | — | CTE | — | — | NED (37) | |
| 22 | Osteosarcoma | M | 14.5 | 4B | CTx | CR | CR | CR | CTE | CM | — | NED (29) | |
| 23 | Ewing | M | 11.6 | 4B | CTx | PR | SD | SD | CTE | CM | — | NED (24) | |
| 24 | Ewing | M | 7.7 | 4 | CTx + Surgery | CR | CR | — | CTE | — | Relapse (7) | DOD (11) | |
| 25 | RMS | M | 0.3 | 4 | CTx | CR | CR | CR | CTE | CM | Relapse (12) | AWD (24) | |
| 26 | Osteosarcoma | F | 16.0 | 4B | CTx + Surgery | CR | CR | CR | CTE | CM | Relapse (12) | Follow up loss (17) | |
| 27 | Osteosarcoma | F | 14.5 | 1B | CTx | SD | SD | — | CTE | — | Progression (5) | DOD (11) | |
| 28 | Synovial sarcoma | F | 15.4 | 4 | CTx + Surgery | CR | CR | CR | CTE | CM | — | NED (14) | |
HDCT, high-dose chemotherapy; HR, high-risk; CTx, chemotherapy; RTx, radiotherapy; SD, stable disease; PD, progressive disease; MEC, melphalan + etoposide + carboplatin; DOD, died of disease; Ewing, Ewing sarcoma family; CR, complete remission; CTE, carboplatin + thiotepa + etoposide; CM, cyclophosphamide + melphalan; NED, no evidence of disease; TRM, treatment-related mortality; DOC, died from other cause; PR, partial remission; RMS, rhabdomyosarcoma; DSRCT, desmoplastic small round-cell tumor; TBI, total body irradiation; AWD, alive with disease; CEC, carboplatin + etoposide + cyclophosphamide; MPNST, malignant peripheral nerve sheath tumor.
*Months from date of last high-dose chemotherapy and autologous stem cell transplantation. †This patient showed increased enhancing lesion after the HDCT/auto-SCT and seemed to have PD, but the lesion decreased without any treatment. The increased enhancing lesion was retrospectively suspected as radiotherapy related change.